RxDoctor Payments Data

Premala Raja, MD

Cardiovascular Disease · Englewood, FLNPI 1194736504

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 46 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$208
  • Abbott$166
  • Johnson & Johnson$152
  • Biotronik Inc.$125
  • E.r. Squibb & Sons, L.L.C.$98
  • Pfizer$97
  • plus $225 from 7 others

What the payments were for

  • Food & beverage$1,03997%
  • Education$333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,072 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$156,650
Medicare patients
407
Services billed
1,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$274,904
EntrestoSacubitril/Valsartan38$76,584
XareltoRivaroxaban49$68,098
Repatha SureclickEvolocumab25$16,887
Metoprolol Succinate416$4,919
Losartan Potassium203$1,519
Atorvastatin Calcium177$1,418
Potassium Chloride86$1,375
ClopidogrelClopidogrel Bisulfate130$1,299
Rosuvastatin Calcium162$1,290
Ezetimibe60$1,247
Amlodipine Besylate199$967
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$915
Carvedilol95$885
Digoxin40$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$274,904275 claims
NovartisEntresto$208$76,58438 claims
Johnson & JohnsonXarelto$152$68,09849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Englewood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →